Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status

Ryan D. Ross, Maleeha Mashiatulla, Alexander Robling, Lisa M. Miller, D. Rick Sumner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Sclerostin and parathyroid hormones are strong negative and positive regulators of bone formation, respectively. The anabolic response induced by intermittent (iPTH) treatment is sclerostin status-dependent. However, the interaction between sclerostin and iPTH at the matrix level is unknown. The goal of the current study was to determine if iPTH treatment affects matrix composition and, if so, whether these effects are dependent on sclerostin status. Humeral trabecular and cortical bone sites from 16 week old male wild-type (WT) and sclerostin knockout (KO) mice, which had been treated with vehicle or iPTH from age 10–16 weeks, were examined by micro-computed tomography (µCT) to measure bone volume, backscatter scanning electron microscopy (bSEM) to assess global mineralization, and Fourier transform infrared microspectroscopy (FTIRM) to examine matrix composition (mineral-to-matrix ratio, crystallinity, collagen cross-link ratio, and carbonate substitution). The FTIRM measurements were restricted to the tissue formed during the 6-week treatment period. iPTH treatment led to increased trabecular bone volume (p 

Original languageEnglish (US)
Pages (from-to)149-157
Number of pages9
JournalCalcified Tissue International
Volume98
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Bone Matrix
Fourier Analysis
Carbonates
Parathyroid Hormone
Osteogenesis
Knockout Mice
Electron Scanning Microscopy
Minerals
Collagen
Tomography
Bone and Bones
Cancellous Bone
Cortical Bone

Keywords

  • Bone quality
  • Matrix composition
  • Mineralization
  • Parathyroid hormone
  • Sclerostin

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status. / Ross, Ryan D.; Mashiatulla, Maleeha; Robling, Alexander; Miller, Lisa M.; Sumner, D. Rick.

In: Calcified Tissue International, Vol. 98, No. 2, 01.02.2016, p. 149-157.

Research output: Contribution to journalArticle

Ross, Ryan D. ; Mashiatulla, Maleeha ; Robling, Alexander ; Miller, Lisa M. ; Sumner, D. Rick. / Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status. In: Calcified Tissue International. 2016 ; Vol. 98, No. 2. pp. 149-157.
@article{e732423435cc491e80f1c9dcc1dc2445,
title = "Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status",
abstract = "Sclerostin and parathyroid hormones are strong negative and positive regulators of bone formation, respectively. The anabolic response induced by intermittent (iPTH) treatment is sclerostin status-dependent. However, the interaction between sclerostin and iPTH at the matrix level is unknown. The goal of the current study was to determine if iPTH treatment affects matrix composition and, if so, whether these effects are dependent on sclerostin status. Humeral trabecular and cortical bone sites from 16 week old male wild-type (WT) and sclerostin knockout (KO) mice, which had been treated with vehicle or iPTH from age 10–16 weeks, were examined by micro-computed tomography (µCT) to measure bone volume, backscatter scanning electron microscopy (bSEM) to assess global mineralization, and Fourier transform infrared microspectroscopy (FTIRM) to examine matrix composition (mineral-to-matrix ratio, crystallinity, collagen cross-link ratio, and carbonate substitution). The FTIRM measurements were restricted to the tissue formed during the 6-week treatment period. iPTH treatment led to increased trabecular bone volume (p ",
keywords = "Bone quality, Matrix composition, Mineralization, Parathyroid hormone, Sclerostin",
author = "Ross, {Ryan D.} and Maleeha Mashiatulla and Alexander Robling and Miller, {Lisa M.} and Sumner, {D. Rick}",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s00223-015-0074-6",
language = "English (US)",
volume = "98",
pages = "149--157",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status

AU - Ross, Ryan D.

AU - Mashiatulla, Maleeha

AU - Robling, Alexander

AU - Miller, Lisa M.

AU - Sumner, D. Rick

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Sclerostin and parathyroid hormones are strong negative and positive regulators of bone formation, respectively. The anabolic response induced by intermittent (iPTH) treatment is sclerostin status-dependent. However, the interaction between sclerostin and iPTH at the matrix level is unknown. The goal of the current study was to determine if iPTH treatment affects matrix composition and, if so, whether these effects are dependent on sclerostin status. Humeral trabecular and cortical bone sites from 16 week old male wild-type (WT) and sclerostin knockout (KO) mice, which had been treated with vehicle or iPTH from age 10–16 weeks, were examined by micro-computed tomography (µCT) to measure bone volume, backscatter scanning electron microscopy (bSEM) to assess global mineralization, and Fourier transform infrared microspectroscopy (FTIRM) to examine matrix composition (mineral-to-matrix ratio, crystallinity, collagen cross-link ratio, and carbonate substitution). The FTIRM measurements were restricted to the tissue formed during the 6-week treatment period. iPTH treatment led to increased trabecular bone volume (p 

AB - Sclerostin and parathyroid hormones are strong negative and positive regulators of bone formation, respectively. The anabolic response induced by intermittent (iPTH) treatment is sclerostin status-dependent. However, the interaction between sclerostin and iPTH at the matrix level is unknown. The goal of the current study was to determine if iPTH treatment affects matrix composition and, if so, whether these effects are dependent on sclerostin status. Humeral trabecular and cortical bone sites from 16 week old male wild-type (WT) and sclerostin knockout (KO) mice, which had been treated with vehicle or iPTH from age 10–16 weeks, were examined by micro-computed tomography (µCT) to measure bone volume, backscatter scanning electron microscopy (bSEM) to assess global mineralization, and Fourier transform infrared microspectroscopy (FTIRM) to examine matrix composition (mineral-to-matrix ratio, crystallinity, collagen cross-link ratio, and carbonate substitution). The FTIRM measurements were restricted to the tissue formed during the 6-week treatment period. iPTH treatment led to increased trabecular bone volume (p 

KW - Bone quality

KW - Matrix composition

KW - Mineralization

KW - Parathyroid hormone

KW - Sclerostin

UR - http://www.scopus.com/inward/record.url?scp=84955698358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955698358&partnerID=8YFLogxK

U2 - 10.1007/s00223-015-0074-6

DO - 10.1007/s00223-015-0074-6

M3 - Article

VL - 98

SP - 149

EP - 157

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 2

ER -